Why the study?
Does labetalol prevent doxorubicin-induced cardiotoxicity in a rat model?
Does labetalol prevent doxorubicin-induced cardiotoxicity in a rat model?
In a rat model, labetalol pre-treatment attenuated doxorubicin-induced cardiotoxicity as evidenced by improved cardiac biomarkers and histopathology.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat model; should not change practice or guide therapy pending human trials.
Objectives: Doxorubicin is a member of anthracycline antibiotic family that is widely used in the treatment of hematological malignances and solid tumors. The present study aimed to investigate the possible modulatory effects of labetalol on doxorubicin-induced cardiotoxicity. Materials and Methods: 30 Wale-Sprague male rats where used in this study. The animals were divided into three groups; Group I as the control, Group II received single dose of doxorubicin (15 mg/kg) and Group III received labetalol (1 mg/kg, po) daily for 10 days and on 8 th day, 1 h after drug administration, a single dose of doxorubicin (15 mg/kg) was given intraperitoneally. Results: We observed an increase in cardiac biomarkers in the doxorubicin group compared with the control group (lactate dehydrogenase, malondialdehyde, troponin I, interleukin-17), whereas pre-treatment with labetalol caused a decrease in cardiac biomarkers. Histopathalogical improvement in cardiac tissue was also observed. Conclusion: Doxorubicin used as an antineoplastic agent induces cardiotoxicity, which limits its use. We concluded that labetalol produces differential effects and protection from doxorubicin-induced cardiotoxicity via amelioration of cardiac biomarkers and histopathological changes.
No takes yet. Share an insight, caveat, or question.
Al‐kuraishy et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: